Company Overview and News
BOSTON (Reuters) - The largest target-date funds for U.S. investors nearing retirement are reporting their worst performance since 2008, as bets on Chinese stocks and Treasuries produced negative returns.
LONDON: Paul McNamara has the kind of track record few bond managers can rival: His emerging markets fund has beaten 95% of peers over the past decade, and he’s ahead of the pack again this year.
MORN GMHLF GMHLY
2018-10-04 seekingalpha - 1
Champion stocks report 25+ annual-dividend increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.5% price-target upsides.
HEP GEO PEGI HMLP GLOP VLP MORN WLKP SIR LAZ SUN PEG WPC LVS DGICA DGICB IVZ
Marsh & McLennan Companies, Inc.’s (MMC - Free Report) unit Marsh recently announced its collaboration with Evident to develop its very first blockchain-based verification solution in the expanding sharing and gig economies. This blockchain solution will streamline the onboarding of gig economy clients, providing easy and simple solutions to the insurance and identity verification process with better reliability, safety and risk management.
MMC 7018 CME FAF NAVG MORN
SAN FRANCISCO – It is nearly impossible to imagine Tesla Inc. without Elon Musk — its chairman, CEO, largest shareholder and public face.
Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or "U.S. Moat Index"), lagged the S&P 500® Index in August (1.94% vs. 3.26%, respectively) but remained only slightly behind for the YTD period (9.23% vs. 9.94%, respectively). International moats on the other hand proved more resilient than the broad international market for the month. The Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN, or "International Moat Index") led the MSCI All Country World Index ex-USA in August (-1.
SRCLP PM TPGTF SRCL TPPTY TPM GWRE LB CVS MORN ESRX
It’s important to differentiate the concept of enterprise free cash flow valuation and the idea of capital-market dependence.
FB APLP APA SNSR AND LIT XOM BFIT GXG SIL KRMA GXF ENB CHII SEP ACTX CHIE GOEX KMI FINX CHIX MMP KMR CVB SRET BOTZ CATH KML GURX GURI MORN ALUM MILN CJHIQ URA ENB ETP LNGR COPX QQQC GURU KMRFZ FANG
CHICAGO and NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Morningstar, Inc. (NASDAQ: MORN), a leading provider of independent investment research, and Nasdaq (Nasdaq: NDAQ), a leading global provider of trading, clearing, exchange technology, listing, information and public company services, today announced an agreement under which Nasdaq will provide the Nasdaq Basic real-time market data feed to Morningstar.
Champion stocks sustain 25+ annual dividend-increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.5% price-target upsides. 46/126 were 'safer' for showing positive annual-returns, and cash-flow yields >dividend-yields 8/24/18.
HEP PM GEO PFG HMLP GLOP PRU SUN BEP PRU PEGI PFK VLP MORN WLKP SIR PRH CVX LAZ PEG WPC PJH
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to MORN / Morningstar, Inc. on message board site Silicon Investor.
as of ET